celecoxib and cox 189

celecoxib has been researched along with cox 189 in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (63.33)29.6817
2010's11 (36.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bhardwaj, A; Dzandzi, J; Tietz, O; Valliant, JF; Wuest, F1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J1
Fricke, J; Jayawardene, S; Kellstein, D; Ott, D1
Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P1
Curran, MP; Lyseng-Williamson, KA1
Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH1
Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S1
Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H1
Hochberg, MC1
Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S1
Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD1
Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH1
Marwali, MR; Mehta, JL1
Deray, G; Montalescot, G; Sibilia, J1
Deray, G; Héloire, F; Valat, JP1
Dougados, M; Gitton, X; Moore, A; Yu, S1
Ashcroft, DM; Chen, LC1
Davis, N; Fricke, J; Krammer, G; Yu, V1
Klotz, U; Shi, S1
Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H1
Elliott, WJ1
Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM1
Honjo, H; Iwamoto, K; Uwai, Y1
Harirforoosh, S; Pettit, WL; Wyatt, JE1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y1
Anstaett, P; Ferrari, S; Gasser, G; Pierroz, V1
Hansen, SH; Skonberg, C; Syed, M1

Reviews

11 review(s) available for celecoxib and cox 189

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome

2005
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Arthritis research & therapy, 2007, Volume: 9, Issue:1

    Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides

2007
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones

2007
Clinical use and pharmacological properties of selective COX-2 inhibitors.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2008
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Current hypertension reports, 2010, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones

2010
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
    The pharmacogenomics journal, 2012, Volume: 12, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides

2012
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones

2014

Trials

11 trial(s) available for celecoxib and cox 189

ArticleYear
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Annals of the rheumatic diseases, 2004, Volume: 63, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides

2004
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
    International journal of clinical practice, 2004, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome

2004
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    The Journal of rheumatology, 2004, Volume: 31, Issue:9

    Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides

2004
Lumiracoxib.
    Drugs, 2004, Volume: 64, Issue:19

    Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Male; Molecular Structure; New Zealand; Organic Chemicals; Osteoarthritis; Oxycodone; Pain; Pyrazoles; Sulfonamides; Terminology as Topic; World Health Organization

2004
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Clinical therapeutics, 2005, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome

2005
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Current medical research and opinion, 2005, Volume: 21, Issue:4

    Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome

2005
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Clinical rheumatology, 2006, Volume: 25, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome

2006
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Arthritis research & therapy, 2006, Volume: 8, Issue:2

    Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome

2006
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Arthritis research & therapy, 2007, Volume: 9, Issue:1

    Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides

2007
Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    The journal of pain, 2008, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebo Effect; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome

2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9

    Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States

2008

Other Studies

9 other study(ies) available for celecoxib and cox 189

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Mar-15, Volume: 26, Issue:6

    Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Iodine Radioisotopes; Molecular Docking Simulation; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Sulfones

2016
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:3

    Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides

2005
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3

    Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2

2006
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
    Pharmacological research, 2010, Volume: 62, Issue:5

    Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides

2010
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
    Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5

    Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis

2010
Two-photon uncageable enzyme inhibitors bearing targeting vectors.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2015, Volume: 14, Issue:10

    Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Lasers; Photons

2015
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32

    Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones

2016